EVUSHELD ( formerly AZD7442 ) long - acting antibody combination authorized for emergency use in the US for pre - exposure prophylaxis ( prevention ) of COVID - 19

A new antibody developed by AstraZeneca has received emergency use approval in the US, according to the company's chief medical officer, Dr. John Wright, who has been involved in testing the virus for the first time since the start of the pandemic.

Source: wallstreet-online.de
Published on 2021-12-09